Clinical trials: High Grade Meningioma, open to volunteers
Residual, Progressive or Recurrent Grade II or III Meningioma
NEO100 and High-Grade Meningioma
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade…
- Trial name
- NCT05023018
- Testing
- NEO100
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neonc Technologies, Inc.
Grade 1 Meningioma, Grade 2 Meningioma
Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma
This phase III trial compares post-surgical surveillance to post-surgical radiation therapy for improving survival without disease progression in clinically low-risk patients with a grade 1 meningioma that is new or that has come…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Recurrent Grade 1 Meningioma
- Trial name
- NCT07785687
- Testing
- Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection
- Volunteers
- 464 people
- Sponsor
- NRG Oncology
High Grade Meningioma
A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas
This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive…
- Trial name
- NCT07613450
- Testing
- SYHA1813, Investigator's Choice Treatment
- Volunteers
- 136 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Recurrent or Progressive High Grade Meningioma
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive…
- Trial name
- NCT06739213
- Testing
- SYHA1813, Investigator's Choice Treatment
- Volunteers
- 56 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
High Grade Glioma, Meningioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET.
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma
- Trial name
- NCT05278208
- Testing
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nationwide Children's Hospital